Genspeed, Virogates Partner on Medical Risk Classification Test

May

Predicting COVID-19 Severity: Leveraging the Host Immune Response to Identify High-Risk Patients and Improve Outcomes

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand.

May

Featured Webinar

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Menu

Genspeed, Virogates Partner on Medical Risk Classification Test

To read the full story....

Breaking News

Biden Administration Funds $1B for COVID-19 Testing in Indian Country

Scope Fluidics Gets CE Mark for Rapid MRSA MDx Panel

NIH Awards Qorvo Biotechnologies $24.4M for Rapid SARS-CoV-2 Antigen Test

In Brief This Week: Exact Sciences, Siemens Healthineers, Seegene, Agilent Technologies, and More

Color Health, Yale Get FDA Emergency Use Authorization for Coronavirus Sample Collection Kits

Veracyte Preliminary Q1 Revenues Up 16 to 19 Percent, CFO to Retire

Predicting COVID-19 Severity: Leveraging the Host Immune Response to Identify High-Risk Patients and Improve Outcomes

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

What's Popular?

CDC-NIH Initiative Provides Roadmap for Broad Use of Rapid COVID-19 Antigen Testing

NIH Awards Qorvo Biotechnologies $24.4M for Rapid SARS-CoV-2 Antigen Test

Australian Firm AnteoTech Obtains CE Marking for COVID-19 Antigen Test, Reader

Lucira Health Nabs OTC EUA for SARS-CoV-2 Test, Expects Q1 Revenues of up to $4.5M

Siemens Healthineers Gets CE Mark for Point-of-Care High-Sensitivity Cardiac Troponin I Test

Sponsorships